Arcus Biosciences, Inc. (RCUS)
PHARMACEUTICAL PREPARATIONS
Arcus Biosciences, Inc. (RCUS) is listed on the New York Stock Exchange, where it has traded since March 15, 2018.
- Listed On
- the New York Stock Exchange
- Listed Since
- March 15, 2018
- Employees
- 601
- Market Cap
- $2.3B
About Arcus Biosciences, Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 220 institutions reported holding RCUS, with 122.4 million shares worth $3.8 billion in aggregate. The largest reported holder was Gilead Sciences, with 31.4 million shares worth $968.8 million. Of the 5 largest holders listed below, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Gilead Sciences | 31,424,760 | $969M | Unchanged |
| BlackRock | 16,416,249 | $506M | Added 7.81% |
| Vanguard | 9,114,122 | $281M | Added 3.08% |
| State Street | 6,029,484 | $186M | Added 11.39% |
| Wellington Management | 5,895,448 | $182M | Reduced 3.19% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is RCUS?
Arcus Biosciences, Inc. (RCUS) is listed on the New York Stock Exchange, where it has traded since March 15, 2018.
Who are the largest institutional holders of RCUS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of RCUS were Gilead Sciences, BlackRock and Vanguard.
How many institutions own RCUS?
220 institutions reported a position in RCUS for the quarter ended June 30, 2026, worth $3.8 billion in total.
Did institutions buy or sell RCUS last quarter?
Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for RCUS.
Every reported institutional holder, plus insider and congressional trades in RCUS, on SentiSense.